What is he best known for?
The fields of study he is best known for:
- Gene
- Cancer
- Internal medicine
His scientific interests lie mostly in Multiple myeloma, Cancer research, Internal medicine, Bone marrow and Bortezomib.
His studies in Multiple myeloma integrate themes in fields like Hematology and Pathology.
His Cancer research research integrates issues from Cell culture, Apoptosis, Protein kinase B, Cell growth and In vivo.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Endocrinology, Surgery and Oncology.
The Bone marrow study combines topics in areas such as Molecular biology, Stromal cell, Immune system and Peripheral blood mononuclear cell.
His Bortezomib research is multidisciplinary, relying on both Proteasome inhibitor, Proteasome, Cancer cell, Signal transduction and Stem cell.
His most cited work include:
- Signatures of mutational processes in human cancer (5372 citations)
- Signatures of mutational processes in human cancer (5372 citations)
- Antitumor activity of thalidomide in refractory multiple myeloma. (2200 citations)
What are the main themes of his work throughout his whole career to date?
Nikhil C. Munshi mainly focuses on Multiple myeloma, Cancer research, Internal medicine, Bortezomib and Bone marrow.
The study incorporates disciplines such as Dexamethasone and Transplantation in addition to Multiple myeloma.
Nikhil C. Munshi has included themes like Cell culture, Cell growth, Apoptosis, Cytotoxic T cell and In vivo in his Cancer research study.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology, Surgery and Oncology.
His Bortezomib study combines topics from a wide range of disciplines, such as Proteasome inhibitor, Proteasome and Pharmacology.
His Bone marrow research incorporates elements of Monoclonal antibody, Stromal cell and Cytokine.
He most often published in these fields:
- Multiple myeloma (65.70%)
- Cancer research (44.69%)
- Internal medicine (31.69%)
What were the highlights of his more recent work (between 2017-2021)?
- Multiple myeloma (65.70%)
- Cancer research (44.69%)
- Internal medicine (31.69%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Multiple myeloma, Cancer research, Internal medicine, Oncology and Computational biology.
Multiple myeloma is represented through his Bortezomib and Lenalidomide research.
His biological study spans a wide range of topics, including Cell culture, Immune system, Immunotherapy, Antigen and Bone marrow.
The concepts of his Cell culture study are interwoven with issues in Apoptosis, microRNA and Cell growth.
His study in the field of Cancer, Progression-free survival, Newly diagnosed and Veterans Affairs also crosses realms of In patient.
His Oncology study incorporates themes from Relapsed refractory, Refractory Multiple Myeloma, Dexamethasone and Minimal residual disease.
Between 2017 and 2021, his most popular works were:
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma (422 citations)
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (149 citations)
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma (130 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Nikhil C. Munshi spends much of his time researching Multiple myeloma, Cancer research, Internal medicine, Oncology and Computational biology.
Nikhil C. Munshi combines subjects such as MEDLINE, APOBEC, Disease, Regulation of gene expression and Bone marrow with his study of Multiple myeloma.
His Bone marrow research incorporates themes from Stromal cell, Downregulation and upregulation and Stem cell.
Nikhil C. Munshi has researched Cancer research in several fields, including Cell culture, Cell growth, Antigen, B-Cell Maturation Antigen and Immunotherapy.
His study in the fields of Cancer, Lenalidomide, Progression-free survival and Retrospective cohort study under the domain of Internal medicine overlaps with other disciplines such as In patient.
His studies deal with areas such as Maintenance therapy and Bortezomib as well as Lenalidomide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
